Three Stocks to Buy Now: Enovix, Apogee Therapeutics, and NexGen Energy
ByAinvest
Friday, Aug 29, 2025 6:32 am ET1min read
APGE--
ENVX--
NXE--
According to Top Wall Street Analysts, three stocks to buy now are Enovix (ENVX), Apogee Therapeutics (APGE), and NexGen Energy (NXE). These stocks received new Buy ratings recently and have a significant upside. Enovix has a 107.25% upside, Apogee Therapeutics has a 169.9% upside, and NexGen Energy has a 40.46% upside. Top Analysts have a success rate of 5-star rankings due to the accuracy and profitability of their ratings over time.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet